IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 64.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,465 shares of the medical research company's stock after selling 9,745 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in IQVIA were worth $1,131,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. boosted its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. increased its stake in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock worth $55,000 after purchasing an additional 99 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Activity at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent research reports. Leerink Partners reissued an "outperform" rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Truist Financial decreased their price target on shares of IQVIA from $265.00 to $261.00 and set a "buy" rating for the company in a research report on Thursday, December 12th. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Finally, Stephens began coverage on IQVIA in a research report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target on the stock. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $252.39.

Read Our Latest Analysis on IQVIA

IQVIA Stock Down 0.9 %

Shares of NYSE:IQV opened at $208.13 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The stock has a market cap of $37.78 billion, a P/E ratio of 27.75, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a fifty day moving average price of $200.67 and a 200 day moving average price of $219.54.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Articles

• Five stocks we like better than IQVIA
• Are Penny Stocks a Good Fit for Your Portfolio?
• 3 Volatility ETFs to Help You Profit from Market Chaos
• Investing in Travel Stocks Benefits
• Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
• Do ETFs Pay Dividends? What You Need to Know
• Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Should You Invest $1,000 in IQVIA Right Now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here